Back to Search
Start Over
Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
- Source :
-
Cancer [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3237. - Publication Year :
- 2024
- Subjects :
- Humans
Protein Kinase Inhibitors therapeutic use
Protein Kinase Inhibitors administration & dosage
Agammaglobulinaemia Tyrosine Kinase antagonists & inhibitors
Treatment Outcome
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Bridged Bicyclo Compounds, Heterocyclic administration & dosage
Sulfonamides therapeutic use
Sulfonamides administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0142
- Volume :
- 130
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 39226085
- Full Text :
- https://doi.org/10.1002/cncr.35530